Agnes E.M. Looijen

Agnes E.M. Looijen

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
GKGonul Hazal Koc
Gonul Hazal Koc
ALAgnes E.M. Looijen
Agnes E.M. Looijen
IHIrene E. van der Horst-Bruinsma
Irene E. van der Horst-Bruinsma
PJPascal Hendrik Pieter De Jong
Pascal Hendrik Pieter De Jong
Objective: The disease course and burden of rheumatoid arthritis (RA) may differ between female and male individuals, but existing data on these differences are limited and often contradictory. Therefore, we investigated whether clinical outcomes and patient-reported outcomes (PROs) differ between female and male patients with RA over time. Methods: All female (n = 286) and male (n = 139) patients with RA according to 1987 and/or 2010 criteria from Treatment in the Rotterdam Early Arthritis Cohort (tREACH), a stratified single-blinded trial with a treat-to-target (T2T) approach and fixed medication protocol, were included. Clinical outcomes include disease activity, medication usage, sustained disease-modifying antirheumatic drug (DMARD)-free remission (SDFR), and radiographic progression. In addition, the following PROs were investigated: general health, pain, functional ability, health-related quality of life, fatigue, productivity loss, and a possible depression or anxiety disorder. For comparisons over time, a mixed model or Cox proportional hazard model was used. The mixed models were adjusted for age, initial treatment, and disease activity (Disease Activity Score in 44 joints [DAS44]). Results: Female patients had a higher DAS44 over time compared to male patients (β 0.36, 95% CI 0.25-0.47, P < 0.001), which also resulted in more treatment adjustments including use of biologic DMARDs (bDMARDs; 36% vs 24%, P < 0.001). Although not significant, first bDMARD survival seemed shorter in female patients (hazard ratio [HR] 1.4, 95% CI 0.8-2.6, P = 0.24). However, no differences were found in SDFR and radiographic progression. With regard to PROs, only functional ability differed significantly between sexes after adjusting for confounders, including disease activity (Health Assessment Questionnaire–Disability Index, β 0.10, 95% CI 0.04-0.17, P < 0.001). Conclusion: Clinical outcomes and PROs are intertwined, and both improve with a T2T management approach. Nevertheless, female patients with RA have higher disease activity, a greater need for bDMARDs—although these have lower efficacy—and more functional impairment over time, underscoring the need for sex-specific management recommendations. (Trial registration number: ISRCTN26791028 )

18 October 2024 in RMD Open
Verified
Journal Article
Open access
PDF file
ALAgnes E.M. Looijen
Agnes E.M. Looijen
SHSelinde V J Snoeck Henkemans
Selinde V J Snoeck Henkemans
AMAnnette H M van der Helm-Van Mil
Annette H M van der Helm-Van Mil
PWPaco M J Welsing
Paco M J Welsing
GKGonul Hazal Koc
Gonul Hazal Koc
PJPascal Hendrik Pieter De Jong
Pascal Hendrik Pieter De Jong
Objectives To investigate whether a combination of general health (Visual Analogue Scale (VAS)), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain (VAS/Numerical Rating Scale (NRS)), quality of life (EQ-5D), fatigue (VAS/NRS) and presenteeism (0%–100% productivity loss) could aid as a screening tool to detect active disease in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Methods RA patients from the tREACH trial and TARA trial (n=683) and PsA patients from the DEPAR cohort (n=525) were included. The association of a deterioration in the aforementioned patient-reported outcome measure (PROM) scores between two consecutive visits and having active disease was assessed. Active disease was defined as a change from disease activity score (DAS) ≤2.4 to DAS >2.4 in RA or Disease Activity Index in Psoriatic Arthritis (DAPSA) ≤14 to DAPSA >14 in PsA. The area under the curve (AUC) of the sum score of deteriorated PROMs was evaluated. Results 4594 RA and 1154 PsA visits were evaluated and active disease occurred in 358 (8%) RA and 177 (15%) PsA visits. In both RA and PsA, a deterioration in general health (VAS), HAQ-DI, EQ-5D and pain (VAS/NRS) was significantly associated with active disease. The combination of these PROMs showed acceptable to excellent discriminative ability (RA AUC=0.76, PsA AUC=0.85). If a cut-point of ≥1 deteriorated PROMs is used, 40% of the visits in which RA patients have remission or low disease activity are correctly specified (specificity of 40%), while 10% of visits with active disease are overlooked (sensitivity of 90%). In PsA, these percentages are 41% and 4%, respectively. Conclusion A combination of general health, HAQ-DI, EQ-5D and pain could aid as a screening tool for active disease in patients with RA and PsA. These data could help facilitate remote monitoring of RA and PsA patients in the future. Trial registration numbers ISRCTN26791028, NTR2754.

9 August 2025 in Rheumatology
Verified
Journal Article
Open access
HDHamit Harun Dag
Hamit Harun Dag
SHSelinde V J Snoeck Henkemans
Selinde V J Snoeck Henkemans
ALAgnes E.M. Looijen
Agnes E.M. Looijen
JHJudith W Heutz
Judith W Heutz
RDRadboud J E M Dolhain
Radboud J E M Dolhain
PJPascal Hendrik Pieter De Jong
Pascal Hendrik Pieter De Jong
Objectives: To investigate whether clinical outcomes and patient-reported outcomes (PROs) differ over 2 years based on the age of onset of RA. Methods: All RA patients from the tREACH trial, a multicentre, stratified, single-blinded trial with a treat-to-target management approach and a fixed medication protocol were included. The age of disease onset was categorized into young-onset RA (YORA) (65 years, n = 98) at the time of diagnosis. Mixed models were used to compare clinical outcomes and PROs over time. The following PROs were included: pain (Numeric Rating Scale), fatigue (visual analogue scale), functional ability (HAQ-Disability Index, HAQ-DI), quality of life (European Quality of Life 5-Dimensions 3-Levels, EQ-5D-3L), and possible depression (Hospital Anxiety and Depression Scale-Depression, HADS-D) or anxiety disorder (HADS-Anxiety, HADS-A). Results: At diagnosis, EORA patients had more swollen joints, erosions and comorbidities than younger patients. However, disease activity remained similar across age groups at diagnosis and over time. After 2 years of follow-up, bDMARD usage was 30%, 30% and 15% in YORA, MORA and EORA patients, respectively. EORA patients also experienced less pain and fatigue over time compared with YORA patients [1 (95% CI 0.5–1.6) and 17.3 mm (11.3–23.4) lower] and MORA patients [0.6 (0.1–1) and 5.8 mm (0.7–10.9) lower]. No other clinically relevant PRO differences were observed. Conclusion: Despite unfavourable prognostic factors at diagnosis, EORA patients have similar outcomes compared with their younger counterparts if a treat-to-target management approach is applied. Notably, fewer EORA patients required bDMARDs to reach the same treatment target.

30 March 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
ALAgnes E.M. Looijen
Agnes E.M. Looijen
RLReinier C A van Linschoten
Reinier C A van Linschoten
JBJan-Dietert Brugma
Jan-Dietert Brugma
DHDirk Jan Hijnen
Dirk Jan Hijnen
PJPascal Hendrik Pieter De Jong
Pascal Hendrik Pieter De Jong
APAnnelieke Pasma
Annelieke Pasma
Background: Despite enormous clinical improvements, due to better management strategies and the availability of biologicals, immune-mediated inflammatory diseases (IMIDs) still have a significant impact on patients’ lives. To further reduce disease burden, provider- as well as patient-reported outcomes (PROs) should be taken into account during treatment and follow-up. Web-based collection of these outcomes generates valuable repeated measurements, which could be used (1) in daily clinical practice for patient-centered care, including shared decision-making; (2) for research purposes; and (3) as an essential step toward the implementation of value-based health care (VBHC). Our ultimate goal is that our health care delivery system is completely aligned with the principles of VBHC. For aforementioned reasons, we implemented the IMID registry. Objective: The IMID registry is a digital system for routine outcome measurement that mainly includes PROs to improve care for patients with IMIDs. Methods: The IMID registry is a longitudinal observational prospective cohort study within the departments of rheumatology, gastroenterology, dermatology, immunology, clinical pharmacy, and outpatient pharmacy of the Erasmus MC, the Netherlands. Patients with the following diseases are eligible for inclusion: inflammatory arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, uveitis, Behçet disease, sarcoidosis, and systemic vasculitis. Generic and disease-specific (patient-reported) outcomes, including adherence to medication, side effects, quality of life, work productivity, disease damage, and activity, are collected from patients and providers at fixed intervals before and during outpatient clinic visits. Data are collected and visualized through a data capture system, which is linked directly to the patients’ electronic health record, which not only facilitates a more holistic care approach, but also helps with shared decision-making. Results: The IMID registry is an ongoing cohort with no end date. Inclusion started in April 2018. From start until September 2022, a total of 1417 patients have been included from the participating departments. The mean age at inclusion was 46 (SD 16) years, and 56% of the patient population is female. The average percentage of filled out questionnaires at baseline is 84%, which drops to 72% after 1 year of follow-up. This decline may be due to the fact that the outcomes are not always discussed during the outpatient clinic visit or because the questionnaires were sometimes forgotten to set out. The registry is also used for research purposes and 92% of the patients with IMIDs gave informed consent to use their data for that. Conclusions: The IMID registry is a web-based digital system that collects provider- and PROs. The collected outcomes are used to improve care for the individual patient with an IMID and facilitate shared decision-making, and they are also used for research purposes. The measurement of these outcomes is an essential step toward the implementation of VBHC.

18 December 2025 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
ALAgnes E.M. Looijen
Agnes E.M. Looijen
PWPaco M. J. Welsing
Paco M. J. Welsing
SBSytske Anne Bergstra
Sytske Anne Bergstra
AMAnnette H. M. van der Helm-Van Mil
Annette H. M. van der Helm-Van Mil
PJPascal Hendrik Pieter De Jong
Pascal Hendrik Pieter De Jong
Remote monitoring of disease activity in patients with rheumatoid arthritis (RA) offers a promising solution to increasing healthcare demands. This study aimed to develop and validate a model using selected clinical and patient-reported outcome measure (PROM) items that efficiently and accurately reflect the original disease activity score (DAS). Data from 5802 visits of 612 patients with RA from the treatment in the Rotterdam Early Arthritis Cohort and TApering strategies in RA trials were randomly split (1:1) into derivation and internal validation sets. An external validation was performed using 4404 visits from 1554 patients with RA from the Early Arthritis Cohort. A model was developed using Least Absolute Shrinkage and Selection Operator (LASSO) regression that incorporated age, sex, disease duration, autoantibody status, and individual PROM items, including visual analogue scale (VAS) general health, all Health Assessment Questionnaire-Disability Index (HAQ-DI) items, VAS pain, and VAS fatigue, to predict the DAS. The model's ability to detect active disease (DAS >2.4) and remission (DAS <1.6) was evaluated using the area under the receiver operating characteristic curve (AUC-ROC), along with sensitivity and specificity across predefined thresholds. The final model included 12 out of 28 predictors: age, sex, disease duration, VAS general health, 7 HAQ-DI items, and VAS pain. It showed excellent discriminative ability for detecting active disease with AUC-ROC values of 0.89 in both the development and internal validation sets, and 0.82 in the external validation set. For detecting remission, the AUC-ROC values were 0.86, 0.85, and 0.82, respectively. Test characteristics were provided for different thresholds. The proposed DAS intended for digital remote assessment combines clinical and PROM items and can accurately and efficiently distinguish between disease activity states in RA, supporting its potential use in remote monitoring in the future.

4 April 2024 in Rheumatology
Verified
Journal Article
Open access
PDF file
ALAgnes E.M. Looijen
Agnes E.M. Looijen
EMElise van Mulligen
Elise van Mulligen
HVHarald E Vonkeman
Harald E Vonkeman
AMAnnette H M van der Helm-Van Mil
Annette H M van der Helm-Van Mil
PJPascal Hendrik Pieter De Jong
Pascal Hendrik Pieter De Jong
To determine whether patient reported outcome measures (PROMs) capturing activity limitations, health impact, pain, fatigue and work ability are responsive and sensitive to changes in disease activity status in patients with early and established rheumatoid arthritis (RA). All early RA patients (n = 557) from the tREACH-trial and established RA patients (n = 188) from the TARA-trial were included. Both studies were multicentre, single-blinded trials with a treat-to-target management approach. The following PROMs were studied: Health Assessment Questionnaire Disability Index(HAQ-DI), morning stiffness severity, EQ-5D, general health, 36-item short form(SF-36), joint pain, fatigue and productivity loss. Mean changes in PROMs between two consecutive visits were compared with changes in disease activity status(remission, low disease activity and active disease) using linear mixed models and standardised response means. Additionally, the proportion of individual observations that showed an expected PROM response to disease activity status alterations was calculated. HAQ-DI, morning stiffness severity, general health, EQ-5D and joint pain demonstrated responsiveness to improvement or worsening of disease activity status in both early and established RA. SF-36 physical and mental component scale, fatigue and productivity loss did not show this effect in both groups. Across nearly all PROMs, the magnitude of change and the proportion of individual observations that reflect a shift from and to active disease remained low. HAQ-DI, morning stiffness severity, EQ-5D, general health and joint pain are responsive to disease activity status alterations on a group level in both early and established RA. For the individual patient the responsiveness of these PROMs is poor. tREACH trial (www.isrctn.com, ISRCTN26791028) and TARA trial (www.onderzoekmetmensen.nl, NTR2754)